Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.
Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.
Gubra-aktien faldt ~8% i går drevet af generel sektorstemning efter Zealands survodutide-data frem for selskabsspecifikke forhold, Ascelia Pharma præsenterer i dag fase 2-data for Orviglance® på ESGAR 2026 forud for den afgørende FDA-beslutning med PDUFA-dato den 3. juli 2026, og vi har opdateret vores investment case på Danske Bank.
We have made only minor adjustments to our Ascelia Pharma one-pager following the Q1 2026 results. With less than two months remaining until the July 3 PDUFA date, the report itself contained limited new information, and the investment case stays largely intact.
Yesterday, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the first quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centered on the status and outlook regarding potential partners and the upcoming potential approval of Orviglance.
Ascelia Pharma is expected to release its Q1 2026 results on 12 May 2026. The following day at 11:00, CEO Magnus Corfitzen will present the results and provide an update on the company's latest developments in a live online event.
The Q1 presentation arrives at a pivotal moment for Ascelia Pharma, with the FDA PDUFA decision date for Orviglance set for 3 July 2026 , and ongoing partnership discussions.
* Orviglance data accepted for presentation at high-quality congress * Cash runway into 2027 * Fair value range updated: SEK 2.0-5.4 (2.1-5.8) Orviglance on track for July approval; cash runway into 2027 Ascelia delivered a quarter largely in line with...
Ascelia Pharma - et svensk-amerikansk biotekselskab med fokus på sjældne kræftsygdomme og diagnostisk billedbehandling, deltog torsdag d. 16. april på vores halvårlige seminar.
